Drug intelligence / Profile preview

teosyal rha redensity

Development stage
Unknown
Lead developer
Teoxane
Modality
Small Molecules
Administration
Intradermal, Superficial Dermal (injection)
01

Overview

Teosyal RHA Redensity is a **dermal filler** consisting of a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogeneous, and biodegradable gel implant composed of both crosslinked and non-crosslinked **hyaluronic acid**. It is produced via bacterial fermentation (streptococcus equi strain) and crosslinked with 1,4-butanediol diglycidyl ether (BDDE). The formulation contains 15 mg/mL sodium hyaluronic acid and 0.3% lidocaine hydrochloride in a physiologic buffer (pH 7.3)[8][5]. Its main mechanism of action is **tissue augmentation** by injecting into the dermis for the correction of moderate to severe dynamic perioral rhytids (wrinkles and folds, especially around the mouth)[2][8]. Teosyal RHA Redensity is designed with both crosslinked (for structure and resilience) and non-crosslinked hyaluronic acid (for hydration and repair)[4][8]. It also includes a blend of amino acids, antioxidants, minerals, and Vitamin B6 to support skin cell renewal and health[4]. The addition of lidocaine ensures comfort during injection. Developed by Teoxane, it is primarily indicated for facial rejuvenation, especially perioral rhytids. The product is administered via intradermal injection, often using blanching serial puncture, linear threading, or cross-hatching techniques[5].

Brand names
Teosyal RHA RedensityRHA Redensity
Other names
resilient hyaluronic acid redensity
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on teosyal rha redensity.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on teosyal rha redensity.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call